Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 17;19(1):771.
doi: 10.1186/s12889-019-7078-5.

Clinical and immunological failure among HIV-positive adults taking first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia

Getinet Abera Lenjiso  1 , Berhanu Seyoum Endale  2   3 , Yadeta Dessie Bacha  4
Affiliations

Clinical and immunological failure among HIV-positive adults taking first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia

Getinet Abera Lenjiso et al. BMC Public Health. .

Abstract

Background: Access to antiretroviral therapy (ART) in Ethiopia has been scaled up since the introduction of the service in 2003. Free ART was launched in 2005, resulting in fewer new human immunodeficiency virus (HIV) infections and deaths from acquired immunodeficiency syndrome (AIDS). However, immunological and clinical failures for first-line ART due to poor adherence and other factors have received less attention. Thus, this study aims to determine the magnitude and associated factors of clinical and immunological failure among HIV-positive adults after six months of first-line ART in Dire Dawa, Eastern Ethiopia.

Methods: A facility-based cross-sectional study was conducted using secondary data of patients on ART in all health facilities providing ART services in Dire Dawa. A total of 949 samples were collected. The data were entered into Epidata version 3.02, and the analysis was performed using SPSS version 16.0. Univariate and multivariate analyses were performed to determine the magnitude of clinical and immunological failure and identify factors significantly associated with the outcome variable.

Results: The magnitude of clinical and immunological failure was 22.7% (n = 215). Of these, 33 (15%) patients were switched to second-line ART. CD4 count ≤100 cells/mm3 (AOR: 1.78, 95% CI: 1.18-2.69), poor adherence (AOR: 2.5, 95% CI: 1.19-5.25), restarting after interruption of ART (AOR: 1.93, 95% CI: 1.23-3.07), regimen change (AOR: 1.50, 95% CI: 1.05-2.15), ambulatory/bedridden functional status at the last visit on ART (AOR: 2.41, 95% CI: 1.22-4.75) and patients who died (AOR: 3.94, 95% CI: 1.64-9.45) had higher odds of failure.

Conclusion: The magnitude of clinical and immunological failure was high. To curb this problem, initiation of ART before the occurrence of severe immune suppression, early detection and management of failure and improved adherence support mechanisms are recommended. Restarting treatment after interruption and regimen changes-should-be-made-cautiously.

Keywords: Adherence; Clinical failure; Functional status; Immunological failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Diagrammatic presentation of the occurrence of clinical and immunological failure among the study subjects in Dire Dawa, Eastern Ethiopia, January 2014
Fig. 2
Fig. 2
Duration for the occurrence of clinical and immunological failure among study subjects in Dire Dawa, Eastern Ethiopia, January 2014
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. UNAIDS. World AIDS day report. Geneva, Switzerland: UNAIDS; 2011. Available from: https://www.unaids.org/sites/default/files/media_asset/JC2216_WorldAIDSd.... Accessed 21 Oct 2018.
    1. World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS response: Epidemic update and health sector progress towards universal access. Progress report. Geneva, Switzerland: WHO; 2011. Available from: https://apps.who.int/iris/bitstream/handle/10665/44787/9789241502986_eng.... Accessed 21 Oct 2018.
    1. FHAPCO. Country progress report on HIV/AIDS response. Addis Ababa, Ethiopia: FHAPCO; 2012. Available from: http://s3.amazonaws.com/zanran_storage/www.unaids.org/ContentPages/25461.... Accessed 21 Oct 2018.
    1. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO; 2006. Available from: https://apps.who.int/iris/bitstream/handle/10665/43554/9789241594677_eng.... Accessed 21 Oct 2018.
    1. FMoH. National Guidelines for Comprehensive HIV Prevention, Care and Treatment in Ethiopia. Addis Ababa, Ethiopia: FMoH; 2014. Available from: https://aidsfree.usaid.gov/sites/default/files/ethiopia_natl_gl_2014.pdf. Accessed 18 Sep 2018.

Substances